(2-chloro-9H-purin-6-yl)-pyridin-3-ylmethyl-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: (2-chloro-9H-purin-6-yl)-pyridin-3-ylmethyl-amine
• 英文别名: 2-chloro-N-(pyridin-3-ylmethyl)-9H-purin-6-amine；2-chloro-N-(pyridin-3-ylmethyl)-7H-purin-6-amine
• 化学式: C₁₁H₉ClN₆
• 分子量: 260.686
• InChiKey: PXWJCNVXTZCXTI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  79.4
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2-chloro-9H-purin-6-yl)-pyridin-3-ylmethyl-amine 、 2-溴丙烷 在 potassium carbonate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 以78%的产率得到2-chloro-9-isopropyl-N-(pyridin-3-ylmethyl)-9H-purin-6-amine
  参考文献：
  名称：

  [EN] NEW PURINE DERIVATIVES
  [FR] NOUVEAUX DERIVES PURIQUES

  摘要：

  公开号：

  WO2004016612A3
• 作为产物：
  描述：

  3-氨甲基吡啶 、 2,6-二氯嘌呤 在 三乙胺 作用下， 以 正丁醇 为溶剂， 反应 1.0h， 以91%的产率得到(2-chloro-9H-purin-6-yl)-pyridin-3-ylmethyl-amine
  参考文献：
  名称：

  [EN] NEW PURINE DERIVATIVES
  [FR] NOUVEAUX DERIVES PURIQUES

  摘要：

  公开号：

  WO2004016612A3

文献信息

• [EN] DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796<br/>[FR] DÉRIVÉS DE L'ADÉNINE ET DE LA 8-AZA-ADÉNINE ET LEURS UTILISATIONS
  申请人：ASTRAZENECA AB

  公开号：WO2009034386A1

  公开（公告）日：2009-03-19

  The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula (I): which have bacterial MurI inhibitory activity and are accordingly useful for their treatment and prophylaxis of bacterial infection, e.g., E.faecalis or E. faeciuminfection. Further, the invention relates to methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of the compounds, to pharmaceutical compositions containing them, and to their use in the manufacture of medicaments of use in the treatment and prevention of various bacterial diseases in a warm-blooded animalsuch as man.

  该发明涉及化合物或其药用可接受的盐，其化学式为（I）：具有细菌MurI抑制活性，因此可用于治疗和预防细菌感染，例如E.faecalis或E. faecium感染。此外，该发明涉及人体或动物体的治疗方法。该发明还涉及化合物的制造方法，含有这些化合物的药物组合物，以及它们在制造用于治疗和预防人类等恒温动物各种细菌疾病的药物中的应用。
• NEW PURINE DERIVATIVES
  申请人：FISCHER Peter Martin

  公开号：US20090325983A1

  公开（公告）日：2009-12-31

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R 1 and R 2 is methyl, ethyl or isopropyl, and the other is H; R 3 and R 4 are each independently H, branched or unbranched C 1 -C 6 alkyl, or aryl, and wherein at least one of R 3 and R 4 is other than H; R 5 is a branched or unbranched C 1 -C 5 alkyl group or a C 1 -C 6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R 6 , R 7 , R 8 and R 9 are each independently H, halogen, NO 2 , OH, OMe, CN, NH 2 , COOH, CONH 2 , or SO 2 NH 2 . A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，且其中至少一个不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团都可以选择地用一个或多个OH基团进行取代；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。本发明的另一个方面涉及包含上述公式1化合物的制药组合物，以及在治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病中使用上述化合物的用途。
• Purine derivatives
  申请人：Cyclacel Limited

  公开号：US07582642B2

  公开（公告）日：2009-09-01

  The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independently H, branched or unbranched C1-C6 alkyl, or aryl, and wherein at least one of R3 and R4 is other than H; R5 is a branched or unbranched C1-C5 alkyl group or a C1-C6 cycloalkyl group, each of which may be optionally substituted with one or more OH groups; R6, R7, R8 and R9 are each independently H, halogen, NO2, OH, OMe, CN, NH2, COOH, CONH2, or SO2NH2. A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

  本发明涉及公式1的化合物或其药学上可接受的盐，其中R1和R2中的一个是甲基、乙基或异丙基，另一个是氢；R3和R4各自独立地是氢、支链或非支链的C1-C6烷基或芳基，并且至少有一个R3和R4不是氢；R5是支链或非支链的C1-C5烷基或C1-C6环烷基，每个基团可以选择性地取代一个或多个OH基团；R6、R7、R8和R9各自独立地是氢、卤素、NO2、OH、OMe、CN、NH2、COOH、CONH2或SO2NH2。 本发明的另一个方面涉及包含公式1化合物的药物组合物，并且使用所述化合物治疗增殖性疾病、病毒性疾病、中风、脱发、中枢神经系统疾病、神经退行性疾病或糖尿病。
• Compounds for improving mRNA splicing
  申请人：The General Hospital Corporation

  公开号：US10676475B2

  公开（公告）日：2020-06-09

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供的化合物有助于改善细胞中的 mRNA 剪接。本文提供的示例化合物可用于改善包含至少一个以核苷酸序列 CAA 结尾的外显子的基因中的 mRNA 剪接。还提供了制备这些化合物的方法和治疗中枢神经系统疾病的方法。
• Exploring 9-benzyl purines as inhibitors of glutamate racemase (MurI) in Gram-positive bacteria
  作者：Bolin Geng、Gloria Breault、Janelle Comita-Prevoir、Randy Petrichko、Charles Eyermann、Tomas Lundqvist、Peter Doig、Elise Gorseth、Brian Noonan

  DOI：10.1016/j.bmcl.2008.06.068

  日期：2008.8

  An early SAR study of a screening hit series has generated a series of 9-benzyl purines as inhibitors of bacterial glutamate racemase (MurI) with micromolar enzyme potency and improved physical properties. X-ray co-crystal EI structures were obtained.